CYP 4.00% 24.0¢ cynata therapeutics limited

new board member, page-8

  1. 47 Posts.
    Good grief ... such mindless impatience.

    GVHD trial underway, asthma preclinical study completed, patents and regulatory approvals progressing ... tech (so far) seems safe and it's effectiveness in the process of being demonstrated ... the CYP story is slowly but surely permeating across the industry ... the company is communicating to the market in a structured and strategic way.

    This is a professional outfit. They are doing their job in a measured and intelligent manner. Do you really want to toss these guys out at this pivotal time (and jeopardize our Fujifilm relationship in the process) just to tart up the PR spin and juice the SP a few cents?? This is a long haul flight not a bike ride to the corner store. Calm yourself brother and play the long game
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.